Just after midnight on the morning of Aug. 7, President Trump’s sweeping “reciprocal” tariffs took effect on dozens of international trading partners, marking another dramatic escalation of the administration’s “America First” trading policy.
AMCP Comment Letter on Medicare Drug Price Negotiation Program Draft Guidance
AMCP recognizes the importance of efforts to make prescription drugs more affordable for Medicare beneficiaries and urges CMS to continually and rigorously oversee the program’s implementation and its broader effects to ensure that it does not unintentionally hinder innovation and the development of new therapies. CMS should monitor the downstream impact of the Medicare Drug Price Negotiation Program on innovation and drug development and take appropriate action as needed to ensure that the United States remains the leader in pharmaceutical innovation.
Related
President Trump signed H.R.1, Republicans’ “big, beautiful” reconciliation bill, into law on July 4, 2025. Starting from that date, the law lays out effective dates and implementation dates for its numerous health provisions over the next few years, and beyond.
AMCP comments on Trump Administration demands for manufacturers to take action on Most-Favored-Nation pricing scheme
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
